Compare KKR & Co Inc (KKR) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Medpace Holdings Inc — how do they compare? KKR & Co Inc trades at $112.63 (market cap $99.55B), while Medpace Holdings Inc trades at $585.03 (market cap $16.66B). The key difference: KKR & Co Inc is far larger — about 6× Medpace Holdings Inc's market cap, and KKR & Co Inc pays a 0.7% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| KKR | MEDP | |
|---|---|---|
Market Cap | $99.55B | $16.66B |
Sector | Financials | Technology |
52-Week High | $149.34 | $620.59 |
52-Week Low | $83.88 | $393.42 |
Enterprise Value | $22.11B | $16.28B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $110.625, up 6.54% today, with strong bullish momentum near its consensus price target of $127.22. Recent earnings beats in Q1 and Q2 2026, alongside a high analyst buy rating of 88.89%, reflect robust operational performance. The company's strategic acquisitions, including Medicover India and Integer Holdings, signal aggressive growth in healthcare and infrastructure sectors.
The outlook for KKR is positive, driven by earnings growth and strategic expansions, but risks include high leverage and market volatility. Upside potential exists if the company maintains its earnings trajectory and executes acquisitions successfully, though investors should monitor debt levels and integration challenges.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
